A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer. Rodriguez Y, Unno K, Truica MI, Chalmers ZR, et al. Cancer Res 2022 Apr 11. pii: 694256. doi: 10.1158/0008-5472.CAN-21-3565.

Read + Share

Amedeo Smart

Independent Medical Education

Rodriguez Y, Unno K, Truica MI, Chalmers ZR, et al. A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer. Cancer Res 2022 Apr 11. pii: 694256. doi: 10.1158/0008-5472.CAN-21-3565.
PMID: 35405009